Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches

Infectious Disease Clinics of North America

Volumn 30, Issue 2, 2016, Pages 491-507

  Holubar, Marisa ^a   Meng, Lina ^b   Deresinski, Stan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Ceftaroline; Daptomycin; Endocarditis; Methicillin; MRSA; Staphylococcus aureus; Vancomycin

Indexed keywords

AFN 1252; ANTIBIOTIC AGENT; BRILACIDIN; CEFTAROLINE; CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DEBIO 1452; DOXYCYCLINE; ERAVACYCLINE; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; LANOPEPDEN; LCB 010371; LEFAMULIN; LINEZOLID; MRX 1; OMADACYCLINE; ORITAVANCIN; PIPERACILLIN PLUS TAZOBACTAM; RADEZOLID; RIFAMPICIN; TEDIZOLID; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IN VITRO STUDY; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIC90; MPRF GENE; MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; BACTEREMIA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84991377608     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2016.02.009     Document Type: Review

References (60)

1. 1 Kalil, A.C., Van Schooneveld, T.C., Fey, P.D., et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections. JAMA, 312(15), 2014, 1552.
2. 2 Cervera, C., Castañeda, X., De La Maria, C.G., et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 58:12 (2014), 1668–1675.
3. 3 Neely, M.N., Youn, G., Jones, B., et al. Are vancomycin trough concentrations adequate for optimal dosing?. Antimicrob Agents Chemother 58:1 (2014), 309–316.
4. 4 Zelenitsky, S., Rubinstein, E., Ariano, R., et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 41:3 (2013), 255–260.
5. 5 Zhanel, G.G., Calic, D., Schweizer, F., et al. New lipoglycopeptides. Drugs 70:7 (2010), 859–886.
6. 6 McCurdy, S.P., Jones, R.N., Mendes, R.E., et al. In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother 59:8 (2015), 5007–5009.
7. 7 Dunne M, Puttagunta S. Clearance of Staphylococcus aureus bacteremia in patients treated with dalbavancin. Poster session presented at: IDWeek 2013, October 2–6; San Francisco, CA.
8. 8 Corey, G.R., Rubinstein, E., Stryjewski, M.E., et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 60 (2014), 787–796.
9. 9 Ruggero, M.A., Peaper, D.R., Topal, J.E., Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis. Infect Dis (Lond) 47:6 (2015), 379–384.
10. 10 Theravance Biopharma Antibiotics, Inc. A phase 3 telavancin Staphylococcus aureus bacteremia trial. NCT02208063 [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT02208063. Accessed June 30, 2015.
11. 11 Bayer, A.S., Mishra, N.N., Sakoulas, G., et al. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58:12 (2014), 7462–7467.
12. 12 Bayer, A.S., Schneider, T., Sahl, H.-G., Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:1 (2013), 139–158.
13. 13 Humphries, R.M., Pollett, S., Sakoulas, G., A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26:4 (2013), 759–780.
14. 14 Culshaw, D., Lamp, K.C., Yoon, M.J., et al. Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 83:2 (2015), 193–197.
15. 15 Liu, C., Bayer, A., Cosgrove, S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:3 (2011), e18–e55.
16. 16 Gasch, O., Camoez, M., Domínguez, M.A., et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother 69:2 (2014), 568–571.
17. 17 Bassetti, M., Nicco, E., Ginocchio, F., et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 36:5 (2010), 459–461.
18. 18 Kullar, R., Casapao, A.M., Davis, S.L., et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 68:12 (2013), 2921–2926.
19. 19 Murray, K., Zhao, J., Davis, S., et al. Early use of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: A matched cohort study. Clin Infect Dis 56:11 (2013), 1562–1569.
20. 20 Otero, L.H., Rojas-Altuve, A., Llarrull, L.I., et al. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci U S A 110:42 (2013), 16808–16813.
21. 21 Sader, H.S., Farrell, D.J., Flamm, R.K., et al. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). J Antimicrob Chemother 70:7 (2015), 2053–2056.
22. 22 Espedido, B.A., Jensen, S.O., van Hal, S.J., Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother 70:3 (2014), 797–801.
23. 23 MacGowan, A.P., Noel, A.R., Tomaselli, S., et al. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 57:6 (2013), 2451–2456.
24. 24 Drusano, G.L., Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 65:Suppl 4 (2010), iv33–iv39.
25. 25 Autry, E.B., Rybak, J.M., Leung, N.R., et al. Pharmacokinetic and pharmacodynamic analyses of ceftaroline in adults with cystic fibrosis. Pharmacotherapy 36:1 (2016), 13–18.
26. 26 Vazquez, J.A., Maggiore, C.R., Cole, P., et al. Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract 23:1 (2015), 39–43.
27. 27 Casapao, A.M., Davis, S.L., Barr, V.O., et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:5 (2014), 2541–2546.
28. 28 Paladino, J.A., Jacobs, D.M., Shields, R.K., et al. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents 44:6 (2014), 557–563.
29. 29 Polenakovik, H.M., Pleiman, C.M., Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 42:5 (2013), 450–455.
30. 30 Ho, T.T., Cadena, J., Childs, L.M., et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67:5 (2012), 1267–1270.
31. 31 Lin, J.C., Aung, G., Thomas, A., et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 19:1 (2013), 42–49.
32. 32 Tattevin, P., Boutoille, D., Vitrat, V., et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 69:7 (2014), 2010–2013.
33. 33 Rybak, J.M., Marx, K., Martin, C.A., Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy 34:11 (2014), 1198–1208.
34. 34 Flamm, R.K., Mendes, R.E., Hogan, P.A., et al. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagn Microbiol Infect Dis 81:4 (2015), 283–289.
35. 35 Burdette, S., Trotman, R., Tedizolid: the first once daily oxazoidinone class antibiotic. Clin Infect Dis 61:8 (2015), 1315–1321.
36. 36 Shorr, A.F., Kunkel, M.J., Kollef, M., Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:5 (2005), 923–929.
37. 37 Wilcox, M.H., Tack, K.J., Bouza, E., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48:2 (2009), 203–212.
38. 38 Park, H.J., Kim, S.-H., Kim, M.-J., et al. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect 65:6 (2012), 505–512.
39. 39 Chan, L.C., Basuino, L., Dip, E.C., et al. Comparative efficacy of tedizolid phosphate (prodrug of tedizolid), vancomycin and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 59:6 (2015), 3252–3256.
40. 40 Chopra, I., Roberts, M., Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:2 (2001), 232–260.
41. 41 Stein, G.E., Babinchak, T., Tigecycline: an update. Diagn Microbiol Infect Dis 75:4 (2013), 331–336.
42. 42 Gardiner, D., Dukart, G., Cooper, A., et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:2 (2010), 229–238.
43. 43 Barber, K.E., Werth, B.J., Rybak, M.J., The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother 70:2 (2015), 505–509.
44. 44 Dilworth, T.J., Ibrahim, O., Hall, P., et al. β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 58:1 (2014), 102–109.
45. 45 Barber, K.E., Rybak, M.J., Sakoulas, G., Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother 70:1 (2015), 311–313.
46. 46 Davis, J.S., Sud, A., O'Sullivan, M.V., et al. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin Infect Dis 62:2 (2016), 173–180.
47. 47 Seah, J., Lye, D.C., Ng, T.-M., et al. Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia. Virulence 4:8 (2013), 734–739.
48. 48 Jang, H., Kim, S., Kim, K.H., et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 49:3 (2009), 395–401.
49. 49 Berti, A.D., Sakoulas, G., Nizet, V., et al. β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:10 (2013), 5005–5012.
50. 50 Berti, A.D., Wergin, J.E., Girdaukas, G.G., et al. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 56:10 (2012), 5046–5053.
51. 51 Moise, P.A., Amodio-Groton, M., Rashid, M., et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57:3 (2013), 1192–1200.
52. 52 Sakoulas, G., Brown, J., Lamp, K.C., et al. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience. Clin Ther 31:9 (2009), 1936–1945.
53. 53 Dhand, A., Sakoulas, G., Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther 36:10 (2014), 1303–1316.
54. 54 Paul, M., Bishara, J., Yahav, D., et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ, 350, 2015, h2219.
55. 55 Claeys, K.C., Smith, J.R., Casapao, A.M., et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 59:4 (2015), 1969–1976.
56. 56 Zasowski E, Claeys K, Roberts K. Retrospective evaluation of daptomycin (DAP) plus ceftaroline fosamil (CPT) versus DAP plus sulfamethoxazole/trimethoprim (SMX/TMP) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). Presented in poster session at the 25th European Congress of Clincial Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 25–28, 2015.
57. 57 Fabre, V., Ferrada, M., Buckel, W.R., et al. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis, 1(2), 2014, ofu046.
58. 58 Miŕo, J.M., Entenza, J.M., Del Río, A., et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 56:8 (2012), 4511–4515.
59. 59 Linasmita, P., Successful management of methicillin-resistant Staphylococcus aureus bacteremia unresponsive to Vancomycin by adding fosfomycin: a case report. J Med Assoc Thai 95:7 (2012), 960–963.
60. 60 Del Rio, A., Gasch, O., Moreno, A., et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 59:8 (2014), 1105–1112.